Two engagements where the diagnosis was the hard part - hidden constraints lost in the noise of early production data.

Complex aseptic bioprocess with a pivotal trial at risk

An eight-week aseptic process running five concurrent production lines — 2D and 3D culture, biomaterials, single-use assemblies, biomimetic growth pods — had outrun the organization’s ability to manage it. Production instability was attributed to the newly launched 3D culture initiation, the most complex step and the obvious suspect.

System-level analysis found otherwise. The binding constraint sat downstream, in the shared media and buffer preparation function that every line depended on. Adjusting launch cadence and redistributing workload relieved it.

Result: a 5× increase in deviation-free yields, pivotal trial completed on schedule, with no additional headcount and no capital spend.

Months of delays from how a refrigerator was used, monitored and maintained

Preclinical tissue engineering · IND-enabling study halted

Product quality had declined sharply enough to prevent initiation of the study. An all-hands technical investigation had run for months across several resource-intensive workstreams without a clear answer, while runway burned.

Rather than add another technical hypothesis, a parallel operational excellence project mapped all five production lines, audited the map against existing SOPs, traced every data path from source to destination, and scored the risks with the operators and subject matter experts who ran the work.

The cluster of high-risk findings pointed at media production. Physical inspection found frost buildup, product stored in door shelving, and alarm notations logged on tracking sheets that had never generated an investigation.

The mechanism: as batch sizes grew, thawing serum at 4°C drove the refrigerator below freezing for extended periods, damaging other media components and consuming uncharacterized growth factor activity. Serum specifications covered the thaw but not the hidden constraint that scale had introduced. Adding to this pain, media expiry dated from the compounding date and ignored the extended thaw entirely, resulting in tired media with damaged growth factors - this is process drift.

Result: the next process turn produced acceptable product, after six months of burn with stalled preclinical development. The first-in-man study opened six months behind schedule; the program went on to secure Fast Track designation and ran seven multiphase clinical trials.

Establishing operational discipline, process monitoring and meaningful controls before a technological leap, a growth inflection, or an outsourcing decision is materially cheaper than diagnosing failure after the fact.